Human Molecular Genetics Advance Access published online on August 5, 2003
Human Molecular Genetics, doi:10.1093/hmg/ddg265
© 2003 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Center for Neurologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Cambridge, MA 02319
* To whom correspondence should be addressed. E-mail: mel_feany{at}hms.harvard.edu.
Transgenic Drosophila expressing human Key Words:
Parkinson's disease, Alzheimer's disease,
Article
Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease
2 Center for Neurologic Diseases, Harvard Medical School, Brigham and Women's Hospital, Cambridge, MA 02319; Department of Physics, Wesleyan University, Middletown, CT 06457
3 Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Ave., Room 514. Boston, MA 02115, USA
Abstract 
-synuclein faithfully replicate essential features of human Parkinson's disease, including age-dependent loss of dopaminergic neurons, Lewy-body-like inclusions, and locomotor impairment. To define the transcriptional program encoding molecular machinery involved in -synuclein pathology, we characterized expression of the entire Drosophila genome at pre-symptomatic, early and advanced disease stages. Fifty-one signature transcripts, including lipid, energy, and membrane transport mRNAs, were tightly associated with -synuclein expression. Most importantly, at the pre-symptomatic stage, when the potential for neuroprotection is greatest, expression changes revealed specific pathology. In age-matched tau transgenic Drosophila the transcription of -synuclein associated genes was normal suggesting highly distinct pathways of neurodegeneration. Temporal profiling of progressive gene expression changes in neurodegenerative disease models provides unbiased starting points for defining disease mechanisms and for identifying potential targets for neuroprotective drugs at pre-clinical stages.-synuclein, tau, gene expression
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Bisaglia, S. Mammi, and L. Bubacco Structural insights on physiological functions and pathological effects of {alpha}-synuclein FASEB J, February 1, 2009; 23(2): 329 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Xun, R. A. Sowell, T. C. Kaufman, and D. E. Clemmer Quantitative Proteomics of a Presymptomatic A53T {alpha}-Synuclein Drosophila Model of Parkinson Disease Mol. Cell. Proteomics, July 1, 2008; 7(7): 1191 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Cao, H.-J. Song, T. Gangi, A. Kelkar, I. Antani, D. Garza, and M. Konsolaki Identification of Novel Genes That Modify Phenotypes Induced by Alzheimer's {beta}-Amyloid Overexpression in Drosophila Genetics, March 1, 2008; 178(3): 1457 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Assayag, E. Yakunin, V. Loeb, D. J. Selkoe, and R. Sharon Polyunsaturated Fatty Acids Induce {alpha}-Synuclein-Related Pathogenic Changes in Neuronal Cells Am. J. Pathol., December 1, 2007; 171(6): 2000 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Scherzer, A. C. Eklund, L. J. Morse, Z. Liao, J. J. Locascio, D. Fefer, M. A. Schwarzschild, M. G. Schlossmacher, M. A. Hauser, J. M. Vance, et al. Molecular markers of early Parkinson's disease based on gene expression in blood PNAS, January 16, 2007; 104(3): 955 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Miller and H. J. Federoff Altered Gene Expression Profiles Reveal Similarities and Differences Between Parkinson Disease and Model Systems Neuroscientist, December 1, 2005; 11(6): 539 - 549. [Abstract] [PDF]
|
|
|
|
 |
|
 G. M. Halliday, A. Ophof, M. Broe, P. H. Jensen, E. Kettle, H. Fedorow, M. I. Cartwright, F. M. Griffiths, C. E. Shepherd, and K. L. Double {alpha}-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease Brain, November 1, 2005; 128(11): 2654 - 2664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Lee, S. Patel, and S.-J. Lee Intravesicular Localization and Exocytosis of {alpha}-Synuclein and its Aggregates J. Neurosci., June 22, 2005; 25(25): 6016 - 6024. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Hauser, Y.-J. Li, H. Xu, M. A. Noureddine, Y. S. Shao, S. R. Gullans, C. R. Scherzer, R. V. Jensen, A. C. McLaurin, J. R. Gibson, et al. Expression Profiling of Substantia Nigra in Parkinson Disease, Progressive Supranuclear Palsy, and Frontotemporal Dementia With Parkinsonism Arch Neurol, June 1, 2005; 62(6): 917 - 921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Greene, A. J. Whitworth, L. A. Andrews, T. J. Parker, and L. J. Pallanck Genetic and genomic studies of Drosophila parkin mutants implicate oxidative stress and innate immune responses in pathogenesis Hum. Mol. Genet., March 15, 2005; 14(6): 799 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Eisenreich, C. Ettenhuber, R. Laupitz, C. Theus, and A. Bacher Isotopolog perturbation techniques for metabolic networks: Metabolic recycling of nutritional glucose in Drosophila melanogaster PNAS, April 27, 2004; 101(17): 6764 - 6769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Baptista, M. R. Cookson, and D. W. Miller Parkin and {alpha}-Synuclein: Opponent Actions in The Pathogenesis of Parkinson'S Disease Neuroscientist, February 1, 2004; 10(1): 63 - 72. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Willingham, T. F. Outeiro, M. J. DeVit, S. L. Lindquist, and P. J. Muchowski Yeast Genes That Enhance the Toxicity of a Mutant Huntingtin Fragment or {alpha}-Synuclein Science, December 5, 2003; 302(5651): 1769 - 1772. [Abstract] [Full Text] [PDF]
|
|